The Risk of Herpes Zoster Events in Patients with Spondyloarthritis and the Effect of BNT162b2 mRNA COVID-19 Vaccine

Bibliographic Details
Title: The Risk of Herpes Zoster Events in Patients with Spondyloarthritis and the Effect of BNT162b2 mRNA COVID-19 Vaccine
Authors: Tal Gazitt, Noa Hayat, Nili Stein, Amir Haddad, Ilan Feldhamer, Arnon Dov Cohen, Walid Saliba, Devy Zisman
Source: Vaccines, Vol 12, Iss 1, p 85 (2024)
Publisher Information: MDPI AG, 2024.
Publication Year: 2024
Collection: LCC:Medicine
Subject Terms: spondyloarthritis, ankylosing spondylitis, psoriatic arthritis, mRNA vaccine, COVID-19, herpes zoster, Medicine
More Details: The data on the risk of herpes zoster (HZ) in spondyloarthropathy (SpA) patients are sparse, especially regarding its association with the novel mRNA COVID-19 vaccines and immunosuppressants. We aimed to evaluate whether SpA diagnosis and/or immunosuppressant use affect HZ risk and the influence of mRNA COVID-19 vaccination. We assessed the association between SpA (psoriatic arthritis (PsA) and ankylosing spondylitis (AS)) diagnoses and HZ in a large population database with patients matched by age and sex to controls. We also assessed the association between the COVID-19 vaccine and new-onset HZ using two nested case–control studies, identifying all new HZ cases diagnosed from 1 January–31 December 2021 within the SpA and general population cohorts, matched randomly by sex, age and HZ index date to controls without HZ. Exposure to mRNA COVID-19 vaccination was ascertained in the 6 weeks prior to the index date both in cases and controls. In our results, the incidence rate of HZ was higher in PsA patients vs. the general population, at 1.03 vs. 0.64 per 100 person-years, respectively (adjusted HR = 1.55; 95%CI, 1.19–2.02). Within the SpA group, Jak-I treatment was associated with a higher risk of developing new-onset HZ (adjusted OR = 3.79; 1.15–12.5). Multivariable conditional logistic regression models we used showed no association between COVID-19 vaccination and new-onset HZ among the SpA patients (OR = 1.46; 0.68–3.14).
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2076-393X
Relation: https://www.mdpi.com/2076-393X/12/1/85; https://doaj.org/toc/2076-393X
DOI: 10.3390/vaccines12010085
Access URL: https://doaj.org/article/3c9b96c82b094ed5bd43c6101424fe1a
Accession Number: edsdoj.3c9b96c82b094ed5bd43c6101424fe1a
Database: Directory of Open Access Journals
More Details
ISSN:2076393X
DOI:10.3390/vaccines12010085
Published in:Vaccines
Language:English